ROYALTY PHARMA OA DL-0001 (RPD F) stock market data APIs
€32.893
0.23(0.7%)
as of January 20, 2026
Try our APIs with
free plan!
ROYALTY PHARMA OA DL-0001 Financial Data Overview
Price chart is built with
Anychart
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Prev. Close
32.893
Open
33.118
High
33.463
Low
32.621
52 wk Range
25.256-34.98
Market Cap
19 445 M
P/E Ratio
22.1633
Shares Outstanding
427 M
Revenue
2 350 M
EPS
0.71
Dividends (Yield)
0.0267
Beta
0.425
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get ROYALTY PHARMA OA DL-0001 data using free add-ons & libraries
Get ROYALTY PHARMA OA DL-0001 Fundamental Data
ROYALTY PHARMA OA DL-0001 Fundamental data includes:
- Net Revenue: 2 350 M
- EBITDA: 1 498 M
- Earnings Per Share: 1
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2021-06-30
- EPS/Forecast: 0.69
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
ROYALTY PHARMA OA DL-0001 News
New
Royalty Pharma to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026
Royalty Pharma plc NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its fourth quarter and full year 2025 financial results on Wednesd...
Systemic Lupus Erythematosus Market to Exhibit Growth at a CAGR of 9.4% During the Forecast Period (2025–2034) Owing to Rising Use of Biologics – Approvals of BENLYSTA and SAPHNELO, Plus a Strong Pipeline | DelveInsight
DelveInsight Business Research LLP The total market size of systemic lupus erythematosus is expected to increase in the 7MM during the forecast period, driven by ongoing clinical research of therapie...
Royalty Pharma to Highlight Accomplishments and Provide Business Update at 44th Annual J.P. Morgan Healthcare Conference
Royalty Pharma plc Royalty funding market reached record high of $10 billion in 2025, powered by synthetic royalties Royalty Pharma maintained industry leadership with announced transactions of $4.7 ...
Royalty Pharma (NASDAQ:RPRX) Is Increasing Its Dividend To $0.235
The board of Royalty Pharma plc (NASDAQ:RPRX) has announced that the dividend on 10th of March will be increased to $0.235, which will be 6.8% higher than last year's payment of $0.22 which covered th...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
